JP2010508362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508362A5 JP2010508362A5 JP2009535436A JP2009535436A JP2010508362A5 JP 2010508362 A5 JP2010508362 A5 JP 2010508362A5 JP 2009535436 A JP2009535436 A JP 2009535436A JP 2009535436 A JP2009535436 A JP 2009535436A JP 2010508362 A5 JP2010508362 A5 JP 2010508362A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hcv
- interferon
- cycloalkyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 108010050904 Interferons Proteins 0.000 claims 12
- 102000014150 Interferons Human genes 0.000 claims 12
- 229940079322 interferon Drugs 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- -1 hydroxy, amino Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 3
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 3
- 102000005741 Metalloproteases Human genes 0.000 claims 3
- 108010006035 Metalloproteases Proteins 0.000 claims 3
- 108060004795 Methyltransferase Proteins 0.000 claims 3
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 3
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- 102000012479 Serine Proteases Human genes 0.000 claims 3
- 108010022999 Serine Proteases Proteins 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- PIEXCQIOSMOEOU-UHFFFAOYSA-N 1-bromo-3-chloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Br)C(=O)N(Cl)C1=O PIEXCQIOSMOEOU-UHFFFAOYSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86385706P | 2006-11-01 | 2006-11-01 | |
| PCT/US2007/083131 WO2008057875A2 (en) | 2006-11-01 | 2007-10-31 | Inhibitors of hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010508362A JP2010508362A (ja) | 2010-03-18 |
| JP2010508362A5 true JP2010508362A5 (enExample) | 2010-10-28 |
Family
ID=39365223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535436A Withdrawn JP2010508362A (ja) | 2006-11-01 | 2007-10-31 | Ｃ型肝炎ウイルスの阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080107623A1 (enExample) |
| EP (1) | EP2086994B1 (enExample) |
| JP (1) | JP2010508362A (enExample) |
| CN (1) | CN101578294A (enExample) |
| NO (1) | NO20091706L (enExample) |
| WO (1) | WO2008057875A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| US8343477B2 (en) * | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| KR20100024920A (ko) * | 2007-05-03 | 2010-03-08 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제 |
| MX2009012093A (es) | 2007-05-10 | 2010-01-25 | Intermune Inc | Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c. |
| AR067180A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Compuestos antivirales |
| KR20100118991A (ko) * | 2008-02-04 | 2010-11-08 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 매크로시클릭 세린 프로테아제 억제제 |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) * | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| CN102458444A (zh) | 2009-05-13 | 2012-05-16 | 英安塔制药有限公司 | 用作丙型肝炎病毒抑制剂的大环化合物 |
| WO2010135748A1 (en) * | 2009-05-22 | 2010-11-25 | Sequoia Pharmaceuticals Inc. | Bimacrocyclic hcv ns3 protease inhibitors |
| US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
| WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
| US8815893B2 (en) * | 2010-02-22 | 2014-08-26 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
| CN106986862A (zh) | 2010-12-22 | 2017-07-28 | Abbvie 公司 | 丙型肝炎抑制剂及其用途 |
| CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN103396351B (zh) * | 2013-08-09 | 2015-10-21 | 山东大学 | 吡咯烷类Bcl-2蛋白小分子抑制剂化合物及其制备、药物组合物与制药用途 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| DK3328827T3 (da) | 2015-07-31 | 2023-10-02 | Univ Johns Hopkins | Prodrugs af glutaminanaloger |
| CN110520118A (zh) | 2017-02-01 | 2019-11-29 | 约翰斯霍普金斯大学 | 谷氨酰胺类似物的前药 |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| CA3097231A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20060199773A1 (en) * | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| US7601709B2 (en) * | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| EP1629000B1 (en) * | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| SI1615613T1 (sl) * | 2003-04-18 | 2010-03-31 | Enanta Pharm Inc | Kinoksalinilni makrociklični inhibitorji serinske proteaze hepatitisa C |
| ATE495185T1 (de) * | 2004-01-21 | 2011-01-15 | Boehringer Ingelheim Int | Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus |
| JP4654239B2 (ja) * | 2004-03-15 | 2011-03-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法 |
| EP1805187A1 (en) * | 2004-10-21 | 2007-07-11 | Pfizer, Inc. | Inhibitors of hepatitis c virus protease, and compositions and treatments using the same |
| TW200738742A (en) * | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
| US7741281B2 (en) * | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| WO2008022006A2 (en) * | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
-
2007
- 2007-10-25 US US11/923,977 patent/US20080107623A1/en not_active Abandoned
- 2007-10-31 CN CNA2007800490456A patent/CN101578294A/zh active Pending
- 2007-10-31 EP EP07863706.3A patent/EP2086994B1/en active Active
- 2007-10-31 JP JP2009535436A patent/JP2010508362A/ja not_active Withdrawn
- 2007-10-31 WO PCT/US2007/083131 patent/WO2008057875A2/en not_active Ceased
-
2009
- 2009-04-29 NO NO20091706A patent/NO20091706L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508361A5 (enExample) | ||
| JP2010508360A5 (enExample) | ||
| JP2012512169A5 (enExample) | ||
| JP2011523651A5 (enExample) | ||
| JP2012504632A5 (enExample) | ||
| JP2012504132A5 (enExample) | ||
| JP2011521965A5 (enExample) | ||
| JP2012504126A5 (enExample) | ||
| JP2012504129A5 (enExample) | ||
| JP2011511841A5 (enExample) | ||
| JP2012511004A5 (enExample) | ||
| JP2013514359A5 (enExample) | ||
| JP2010510234A5 (enExample) | ||
| JP2012528161A5 (enExample) | ||
| JP2007535491A5 (enExample) | ||
| ES2354282T3 (es) | Análogos peptídicos inhibidores de la hepatitis c. | |
| AU2003202347B2 (en) | Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of NS3 (Hepatitis C) | |
| ES2290425T3 (es) | Tripeptidos heterociclicos en calidad de inhibidores de la hepatitis c. | |
| JP2007515405A5 (enExample) | ||
| JP2013521279A5 (enExample) | ||
| JP2007534636A5 (enExample) | ||
| JP2005529069A5 (enExample) | ||
| JP2014504643A5 (enExample) | ||
| JP2012523415A5 (enExample) | ||
| JP2011520906A5 (enExample) |